Novo Nordisk A/S (FRA:NOVA)
Germany · Delayed Price · Currency is EUR | Market Cap | 182.10B -15.9% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.69 |
| Forward PE | 15.59 |
| Dividend | 1.11 (2.79%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 6,982 |
| Open | 41.30 |
| Previous Close | 41.00 |
| Day's Range | 40.50 - 42.00 |
| 52-Week Range | 30.45 - 54.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
PepsiCo ending coverage for prescription weight-loss drugs, Bloomberg reports
Some PepsiCo (PEP) employees were notified this week that weight-loss drugs such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound will no longer be covered by their company…
Novo Nordisk price target raised to DKK 275 from DKK 250 at JPMorgan
JPMorgan raised the firm’s price target on Novo Nordisk (NVO) to DKK 275 from DKK 250 and keeps a Neutral rating on the shares.
Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851
Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase…
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
Scholar Rock (SRRK) announced it has removed Catalent Indiana (NVO) as a commercial fill-finish facility from its apitegromab Biologics License Application for the treatment of spinal muscular atrophy...
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump
Celon Pharma's experimental semaglutide product Reduzek, a generic alternative to Novo Nordisk's Wegovy and Ozempic, matched the blockbuster weight-loss drugs in an early-stage bioequivalence study,...
Novo Nordisk testing lower doses of oral Wegovy, Reuters reports
Novo Nordisk (NVO) is testing lower doses of oral Wegovy to identify the minimum effective dose, a move that could improve tolerability, accessibility, and economics while helping defend its position…
Novo Nordisk Tests Lower-Dose Wegovy Pill in 450-Patient Study
Novo Nordisk has begun testing a lower-dose Wegovy pill in a 450-patient study, a pipeline move that could reshape GLP-1 pricing and competition. The post Novo Nordisk Tests Lower-Dose Wegovy Pill in ...
Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills
The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying ...
Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market
The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs.
Novo begins study to find lowest effective dose for Wegovy pill
Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to find the lowest dose that still helps patients lose weight, according to a U.S. government databa...
Eli Lilly, Stock Of The Day, Is Erasing Novo's Early Lead In Weight-Loss Pills
Eli Lilly is Tuesday's IBD Stock Of The Day. Shares are staring down two potential entries as the weight-loss kingpin gains on Novo Nordisk.
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
Novo Nordisk downgraded to Hold from Buy at Berenberg
Berenberg downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 305, down from DKK 325. The firm says valuation multiple expansion from here will require…
Novo Nordisk downgraded to Hold from Buy at Berenberg
Berenberg downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 305, down from DKK 325. The firm says valuation multiple expansion from here will require…
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
They are way more than just GLP-1 stocks.
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
The Wegovy pill missed analysts' expectations in the second quarter. However, Novo Nordisk is still the leader in the market for oral weight loss drugs.
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)
Novo Nordisk ($NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly ($LLY) over what it alleges is false advertising about weight-loss medications.
Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly
Shares in Danish drugmaker Novo Nordisk ($NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters in an interview…
Novo CEO says obesity market won’t be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take...
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
Competition has to be fierce, but competition also has to be fair, says Novo Nordisk CEO Doustdar
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-q pill, competition in the weight-loss drug space, and more.